Impact of SGLT2 Inhibitors on Chronic Peritoneal Dialysis Patients.

Recruiting now · Not applicable

Conditions studied: End Stage Chronic Renal Failure

In brief

This project aims to examine the effects of six-month treatment with selective SGLT2 inhibitor dapagliflozin in patients with end-stage kidney disease on chronic peritoneal dialysis. Methods: A prospective, open label, single-arm interventional clinical trial, will conduct at Nizwa Hospital from March 1st, 2026, to August 31th , 2026, and includes thirty (30) end-stage kidney disease diabetic and non-diabetic patients on chronic peritoneal dialysis, will receive selective SGLT2i Dapagliflozin 10 mg once daily (OD). Clinical and laboratory parameters will be assessed at baseline, then three and six months after drug initiation. The primary outcomes are:1- change in ultrafiltration volume, 2- change in Kt/V (dialysis adequacy), 3. Change in the mean 24-hour urine volume.

Key facts

Study ID

NCT07491042

Run by

Oman Ministry of Health

People needed

38

Starts

2026-04-01

Expected to finish

2027-01-31

Last updated by the study team

2026-03-24

Who can join

Age: 13 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• o age equal to or more than13 years.
• All genders.
• All patients undergoing chronic Peritoneal Dialysis.
• Urine output equal or more than 150 ml/24 hours.

You may not qualify if…

• o Age less than 13 years
• Patients with type I diabetes mellitus.
• Patients with recurrent urinary tract infection (UTI) or peripheral vascular diseases (P.V.D).
• Patients with urine output less than 150 ml/24hours.
• Patients with recurrent hypoglycemic episodes
• Patients with acute or chronic liver disease,
• Patients who refuse to participate in the study.
• peritoneal Dialysis catheter (PDC) related peritonitis in last 3 months

Where it is running

• Jehad Badawi AL LAHAM — Nizwa, Oman (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.